BTIG Starts Coverage on Tiziana With Buy Rating as Key MS Trial Nears Nasal foralumab aims to cut brain inflammation in SPMS and MSA ahead of October INFORM-MS data. Credit: Tiziana Life Sciences Subscribe now Already have an account? Sign in.
